cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Arrowhead Pharmaceuticals Inc
15 own
22 watching
Current Price
$36.74
$-0.27
(-0.73%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,892.97M
52-Week High
52-Week High
56.25
52-Week Low
52-Week Low
26.81
Average Volume
Average Volume
0.62M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization3,892.97M
icon52-Week High56.25
icon52-Week Low26.81
iconAverage Volume0.62M
iconDividend Yield--
iconP/E Ratio--
What does the Arrowhead Pharmaceuticals Inc do?
Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Read More
How much money does Arrowhead Pharmaceuticals Inc make?
News & Events about Arrowhead Pharmaceuticals Inc.
Business Wire
26days ago
Takeda (TSE:4502/NYSE:TAK) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced topline results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD). The...
Business Wire
1month ago
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 9, 2023, at 8:30 a.m. ET, it will present topline data from the SEQUOIA Phase 2 study evaluating fazirsiran and provide an outline of a Phase 3 study that was co-developed with and will be run by Takeda. Fazirsiran is...
Business Wire
1month ago
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN). This milestone was triggered by the first subject enrolled in Amgens Phase 3 trial of olpasiran. Arrowhead is further eligible to receive up to an additional $535 million in aggregate...
TheStreet.com
1month ago
Avidity Biosciences roared higher after announcing favorable data delivering RNA medicines to muscle tissue.Avidity Biosciences roared higher after announcing favorable data delivering RNA medicines to muscle tissue.Hours after Alex Ovechkin became the first NHL player to score 800 goals with one ...
Globe Newswire
2 months ago
Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK and PASADENA, Calif., Nov. 09...
Frequently Asked Questions
Frequently Asked Questions
What is Arrowhead Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Arrowhead Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Arrowhead Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Arrowhead Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Arrowhead Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Arrowhead Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Arrowhead Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Arrowhead Pharmaceuticals Inc?
plus_minus_icon
What percentage is Arrowhead Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Arrowhead Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$36.74
$-0.27
(-0.73%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00